Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07809945) titled 'A Study of IBI3046 in Participants With Overweight or Obesity' on Sept. 3.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Investigator, Outcomes Assessor).
Primary Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Condition:
Obesity and Overweight
Intervention:
Drug: IBI3046
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: September 15, 2026
Target Sample Size: 128
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/study/NCT07809945
P...